TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).

Keith T Flaherty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.